vs
Arteris, Inc.（AIP）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Arteris, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.0倍（$20.1M vs $19.6M），Arteris, Inc.净利率更高（-42.2% vs -177.4%，领先135.2%），Arteris, Inc.同比增速更快（30.0% vs -11.5%），Arteris, Inc.自由现金流更多（$3.0M vs $-23.1M），过去两年Arteris, Inc.的营收复合增速更高（24.7% vs -12.2%）
Arteris公司是一家跨国科技企业，总部位于美国加利福尼亚州坎贝尔，主营片上网络（NoC）知识产权以及系统芯片（SoC）集成自动化软件的研发，产品用于各类半导体芯片与芯粒设计，客户覆盖汽车电子、人工智能、机器学习、企业计算、通信、消费电子、工业以及航空航天国防等多个领域。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AIP vs LAB — 直观对比
营收规模更大
AIP
是对方的1.0倍
$19.6M
营收增速更快
AIP
高出41.5%
-11.5%
净利率更高
AIP
高出135.2%
-177.4%
自由现金流更多
AIP
多$26.1M
$-23.1M
两年增速更快
AIP
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.1M | $19.6M |
| 净利润 | $-8.5M | $-34.7M |
| 毛利率 | 90.8% | 48.5% |
| 营业利润率 | -42.0% | -168.5% |
| 净利率 | -42.2% | -177.4% |
| 营收同比 | 30.0% | -11.5% |
| 净利润同比 | -3.7% | -28.8% |
| 每股收益（稀释后） | $-0.19 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIPLAB
| Q4 25 | $20.1M | — | ||
| Q3 25 | $17.4M | $19.6M | ||
| Q2 25 | $16.5M | $21.8M | ||
| Q1 25 | $16.5M | $40.8M | ||
| Q4 24 | $15.5M | — | ||
| Q3 24 | $14.7M | $22.1M | ||
| Q2 24 | $14.6M | $22.5M | ||
| Q1 24 | $12.9M | $45.5M |
净利润AIPLAB
| Q4 25 | $-8.5M | — | ||
| Q3 25 | $-9.0M | $-34.7M | ||
| Q2 25 | $-9.1M | $-33.5M | ||
| Q1 25 | $-8.1M | $-26.0M | ||
| Q4 24 | $-8.2M | — | ||
| Q3 24 | $-7.7M | $-26.9M | ||
| Q2 24 | $-8.3M | $-45.7M | ||
| Q1 24 | $-9.4M | $-32.2M |
毛利率AIPLAB
| Q4 25 | 90.8% | — | ||
| Q3 25 | 89.9% | 48.5% | ||
| Q2 25 | 89.4% | 48.8% | ||
| Q1 25 | 90.8% | 48.4% | ||
| Q4 24 | 89.8% | — | ||
| Q3 24 | 90.1% | 54.9% | ||
| Q2 24 | 90.0% | 46.1% | ||
| Q1 24 | 88.7% | 53.1% |
营业利润率AIPLAB
| Q4 25 | -42.0% | — | ||
| Q3 25 | -50.1% | -168.5% | ||
| Q2 25 | -50.0% | -118.1% | ||
| Q1 25 | -46.6% | -80.8% | ||
| Q4 24 | -45.9% | — | ||
| Q3 24 | -53.8% | -120.9% | ||
| Q2 24 | -51.1% | -134.5% | ||
| Q1 24 | -70.5% | -132.2% |
净利率AIPLAB
| Q4 25 | -42.2% | — | ||
| Q3 25 | -51.6% | -177.4% | ||
| Q2 25 | -55.3% | -153.7% | ||
| Q1 25 | -49.1% | -63.8% | ||
| Q4 24 | -53.0% | — | ||
| Q3 24 | -52.2% | -122.0% | ||
| Q2 24 | -57.2% | -203.3% | ||
| Q1 24 | -72.6% | -70.6% |
每股收益（稀释后）AIPLAB
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $-0.21 | $-0.09 | ||
| Q2 25 | $-0.22 | $-0.09 | ||
| Q1 25 | $-0.20 | $-0.07 | ||
| Q4 24 | $-0.19 | — | ||
| Q3 24 | $-0.20 | $-0.07 | ||
| Q2 24 | $-0.22 | $-0.12 | ||
| Q1 24 | $-0.25 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.9M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-14.6M | $399.7M |
| 总资产 | $115.0M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AIPLAB
| Q4 25 | $33.9M | — | ||
| Q3 25 | $39.0M | $129.4M | ||
| Q2 25 | $38.0M | $158.6M | ||
| Q1 25 | $42.3M | $150.9M | ||
| Q4 24 | $43.8M | — | ||
| Q3 24 | $48.7M | $210.6M | ||
| Q2 24 | $45.8M | $269.8M | ||
| Q1 24 | $44.8M | $287.1M |
总债务AIPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益AIPLAB
| Q4 25 | $-14.6M | — | ||
| Q3 25 | $-11.4M | $399.7M | ||
| Q2 25 | $-7.5M | $424.5M | ||
| Q1 25 | $-4.8M | $454.6M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $2.2M | $489.3M | ||
| Q2 24 | $5.3M | $510.3M | ||
| Q1 24 | $9.5M | $577.3M |
总资产AIPLAB
| Q4 25 | $115.0M | — | ||
| Q3 25 | $107.7M | $539.6M | ||
| Q2 25 | $106.9M | $557.0M | ||
| Q1 25 | $98.3M | $579.6M | ||
| Q4 24 | $106.1M | — | ||
| Q3 24 | $97.7M | $681.5M | ||
| Q2 24 | $96.4M | $708.7M | ||
| Q1 24 | $101.4M | $777.7M |
负债/权益比AIPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $3.0M | $-23.1M |
| 自由现金流率自由现金流/营收 | 15.1% | -118.1% |
| 资本支出强度资本支出/营收 | 0.7% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $5.3M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流AIPLAB
| Q4 25 | $3.2M | — | ||
| Q3 25 | $3.2M | $-22.2M | ||
| Q2 25 | $-2.5M | $-20.7M | ||
| Q1 25 | $2.9M | $-30.3M | ||
| Q4 24 | $-2.6M | — | ||
| Q3 24 | $1.1M | $-27.9M | ||
| Q2 24 | $311.0K | $-39.0M | ||
| Q1 24 | $477.0K | $-62.5M |
自由现金流AIPLAB
| Q4 25 | $3.0M | — | ||
| Q3 25 | $2.5M | $-23.1M | ||
| Q2 25 | $-2.8M | $-22.6M | ||
| Q1 25 | $2.7M | $-35.3M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $1.1M | $-30.1M | ||
| Q2 24 | $264.0K | $-41.0M | ||
| Q1 24 | $281.0K | $-63.3M |
自由现金流率AIPLAB
| Q4 25 | 15.1% | — | ||
| Q3 25 | 14.2% | -118.1% | ||
| Q2 25 | -17.2% | -103.6% | ||
| Q1 25 | 16.2% | -86.6% | ||
| Q4 24 | -17.3% | — | ||
| Q3 24 | 7.4% | -136.4% | ||
| Q2 24 | 1.8% | -182.2% | ||
| Q1 24 | 2.2% | -138.9% |
资本支出强度AIPLAB
| Q4 25 | 0.7% | — | ||
| Q3 25 | 4.1% | 4.5% | ||
| Q2 25 | 2.2% | 8.7% | ||
| Q1 25 | 1.1% | 12.4% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | 10.2% | ||
| Q2 24 | 0.3% | 8.6% | ||
| Q1 24 | 1.5% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
